Featured Research

from universities, journals, and other organizations

Potent radiation treatment provides tumor control for patients with inoperable lung cancer

Date:
March 18, 2010
Source:
JAMA and Archives Journals
Summary:
Early findings suggest a radiation therapy that involves numerous highly-focused and potent radiation beams provides targeted tumor control in nearly all patients, reduces treatment-related illness, and may ultimately improve survival for patients with inoperable non-small cell lung cancer, according to a new study.

Early findings suggest a radiation therapy that involves numerous highly-focused and potent radiation beams provides targeted tumor control in nearly all patients, reduces treatment-related illness, and may ultimately improve survival for patients with inoperable non-small cell lung cancer, according to a study in the March 17 issue of JAMA, a theme issue on cancer.

Related Articles


Robert Timmerman, M.D., of the University of Texas Southwestern Medical Center, Dallas, presented the findings of the study at a JAMA media briefing.

Patients with inoperable early stage lung cancer are generally offered conventional radiation treatment (most commonly given during 20-30 outpatient treatments) or observed without specific cancer therapy. "Outcomes are not ideal with either approach. Conventional radiotherapy fails to durably control the primary lung tumor in 60 percent to 70 percent of patients. More than half of patients ultimately die specifically from progressive lung cancer with observation, and 2-year survival is less than 40 percent with either approach," the authors write. Stereotactic body radiation therapy (SBRT) is a noninvasive cancer treatment in which numerous small, highly focused, and accurate radiation beams are used to deliver potent doses in 1 to 5 treatments to tumor targets.

Dr. Timmerman and colleagues conducted the Radiation Therapy Oncology Group (RTOG) 0236 trial, the first North American multicenter, cooperative group study to test SBRT in treating medically inoperable patients with early stage non-small cell lung cancer. The Phase 2 study included patients 18 years or older with biopsy-proven peripheral T1-T2N0M0 non-small cell tumors (measuring less than 5 cm. in diameter) and medical conditions that would not allow surgical treatment. Radiation treatment lasted between 1.5 and 2 weeks. The study opened May 2004 and closed October 2006, with data analyzed through August 2009. The final study population included 55 patients (44 with T1 tumors and 11 patients with T2 tumors), with a median (midpoint) follow-up of 34.4 months.

The primary outcome measured for the study was 2-year actuarial primary tumor control; secondary end points were disease-free survival (i.e., primary tumor, involved lobe, regional, and disseminated recurrence [the reappearance or return of a cancer in multiple areas of the body]), treatment-related toxicity and overall survival.

Of all the patients in the study, only one experienced a documented tumor recurrence or progression at the primary site. The 3-year primary tumor control rate was 97.6 percent. Three patients had recurrence within the involved lobe; the 3-year primary tumor and involved lobe (local) control rate was 90.6 percent. Combining local and regional failures, the 3-year local-regional control rate was 87.2 percent. Disseminated recurrence as some component of recurrence was reported in 11 patients. The 3-year rate of disseminated failure was 22.1 percent with 8 such failures occurring prior to 24 months.

Disease-free survival and overall survival at 3 years were 48.3 percent and 55.8 percent, respectively. Median disease-free survival and overall survival for all patients were 34.4 months and 48.1 months, respectively. Seven patients (12.7 percent) and 2 patients (3.6 percent) were reported to experience protocol-specified treatment-related grade 3 and 4 adverse events, respectively. No grade 5 treatment-related adverse events were reported. Higher grades indicate greater severity of adverse event, with grade 5 indicating death.

"The main finding in this prospective study was the high rate of primary tumor control (97.6 percent at 3 years). Primary tumor control is an essential requirement for the cure of lung cancer," the authors write. "Stereotactic body radiation therapy as delivered in RTOG 0236 provided more than double the rate of primary tumor control than previous reports describing conventional radiotherapy."

"The RTOG 0236 trial demonstrated that technologically intensive treatments like SBRT can be performed in a cooperative group so long as the proper infrastructure and support are put in place. The RTOG will be building on RTOG 0236 to (l) design a trial to address the rather high rate of disseminated failure observed after treatment, (2) complete a trial to determine a safe and effective dose for central lung tumors and (3) complete a trial to refine the dose of SBRT for peripheral tumors."


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal Reference:

  1. Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy. Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer. JAMA, 2010; 303 (11): 1070-1076 [link]

Cite This Page:

JAMA and Archives Journals. "Potent radiation treatment provides tumor control for patients with inoperable lung cancer." ScienceDaily. ScienceDaily, 18 March 2010. <www.sciencedaily.com/releases/2010/03/100316101552.htm>.
JAMA and Archives Journals. (2010, March 18). Potent radiation treatment provides tumor control for patients with inoperable lung cancer. ScienceDaily. Retrieved November 29, 2014 from www.sciencedaily.com/releases/2010/03/100316101552.htm
JAMA and Archives Journals. "Potent radiation treatment provides tumor control for patients with inoperable lung cancer." ScienceDaily. www.sciencedaily.com/releases/2010/03/100316101552.htm (accessed November 29, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Saturday, November 29, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Rural India's Low-Cost Sanitary Pad Revolution

Rural India's Low-Cost Sanitary Pad Revolution

AFP (Nov. 28, 2014) — One man hopes his invention -– a machine that produces cheap sanitary pads –- will help empower Indian women. Duration: 01:51 Video provided by AFP
Powered by NewsLook.com
Research on Bats Could Help Develop Drugs Against Ebola

Research on Bats Could Help Develop Drugs Against Ebola

AFP (Nov. 28, 2014) — In Africa's only biosafety level 4 laboratory, scientists have been carrying out experiments on bats to understand how virus like Ebola are being transmitted, and how some of them resist to it. Duration: 01:18 Video provided by AFP
Powered by NewsLook.com
WHO Says Male Ebola Survivors Should Abstain From Sex

WHO Says Male Ebola Survivors Should Abstain From Sex

Newsy (Nov. 28, 2014) — WHO cites four studies that say Ebola can still be detected in semen up to 82 days after the onset of symptoms. Video provided by Newsy
Powered by NewsLook.com
Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins